Argenx Se ADR (ARGX) Stock Price, Quote & News

Company Profile

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, gr...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 10 703 8441

Website: argenx.com

Address:

Laarderhoogtweg 25, Amsterdam, Netherlands

StreakGeek Jul. 2 at 5:45 PM

$CTAS $IOT $QSR $ARGX mig

0 · Reply

moneybag888 Jul. 2 at 5:09 PM

$ARGX new ATH $953.58

0 · Reply

BarbaraSmith247 Jul. 2 at 3:59 PM

BofA raised $ARGX PT to $1,088 from $1,016 and reiterated Buy. After the recent Myositis investor event, they added standalone value for immune-mediated necrotizing myopathy (INM) into the model. The new subgroup disclosure looks like an incremental positive for the long-term setup.

0 · Reply

Quantumup Jul. 2 at 3:33 PM

BofA y'day⬆️Top Pick $ARGX to $1,088 from $1016, reitd Buy/said—Following ARGX's recent Myositis Investor Event (see our June 24 note), we add standalone value for immune-mediated necrotizing myopathy (INM) to our model. The new disclosure that the INM subgroup was the key driver of the clinically meaningful responses in phase 2 (>60% of patients enrolled) and KOL feedback underscoring the high unmet need and clear biological rationale for Vyvgart in INM gives us increased confidence in the potential for a positive phase 3 readout in 3Q. We are also encouraged by INM receiving BTD and the company's alignment with regulators on the filing path. We think INM represents an attractive commercial opportunity given the lack of approved therapies and high morbidity and view it as a key entry point into rheumatology by opening the door to further expand the Vyvgart franchise. We reiterate our Buy rating with new $1,088/€955 ΡΟ. ARGX remains a top pick in 2026 as we head into a catalyst-rich 2H.

0 · Reply

leonbnu Jun. 23 at 6:39 PM

$ARGX wtf ? $60 drop ?

0 · Reply

Biodro Jun. 23 at 1:35 AM

$ARGX Hmmmmm!!!!

0 · Reply

Night_Owl_Biotech Jun. 21 at 10:24 PM

$ALNY 's share price & valuation has dropped so meaningfully since Thanksgiving, we now include ALNY in our non-BP trackers. Analysts forecast ALNY to generate slightly more revenues over the next 5 years as $ARGX , albeit at slightly lower gross margins due to ALNY's royalty obligation to $SNY , yet ARGX's enterprise value is 36% higher. Analysts forecast both bio's 10 year revenues to be within 3%. The attached graph visualizes how analysts believe both have virtally identical revenue profiles yet because of the disconnect in valuation, ALNY trades at meaningfully lower multiples. We're only sharing an observation. This is not investment advice. There may be very good reasons for the disconnect. If anyone can share a perspective, it would be genuinely appreciated. $XBI $IBB

0 · Reply